Stay updated on Hyperthermia Immunotherapy in Abdominal-Pelvic Malignancies Clinical Trial
Sign up to get notified when there's something new on the Hyperthermia Immunotherapy in Abdominal-Pelvic Malignancies Clinical Trial page.

Latest updates to the Hyperthermia Immunotherapy in Abdominal-Pelvic Malignancies Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedUpdate includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. The core effect is informing users about possible delays and the current open status of the NIH Clinical Center.SummaryDifference4%
- Check18 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.1%
- Check32 days agoChange DetectedUpdate to v3.0.2 with removal of 'Back to Top'; overall, no substantive changes to core content, pricing, stock, or time slots.SummaryDifference0.2%
- Check39 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check46 days agoChange DetectedThe web page has been updated to include new drug information for Retifanlimab and spartalizumab, along with additional content related to cancer treatment and immunotherapy. The facility name and specific location details for Beijing have also been added.SummaryDifference4%
- Check61 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Hyperthermia Immunotherapy in Abdominal-Pelvic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Hyperthermia Immunotherapy in Abdominal-Pelvic Malignancies Clinical Trial page.